The underlying tendency is to the upside for shares in Mediclinic International plc and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated. Investors have an opportunity to buy the stock and target the GBX 600.
Summary
The company presents an interesting fundamental situation from a short-term investment perspective.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company appears to be poorly valued given its net asset value.
Sales forecast by analysts have been recently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
According to forecast, a sluggish sales growth is expected for the next fiscal years.
The group shows a rather high level of debt in proportion to its EBITDA.
The company is not the most generous with respect to shareholders' compensation.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Subsector Hospitals, Clinics & Primary Care Services
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.